相关实验视频

Updated: Jun 16, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

在子宫癌肉瘤中TROP2表达和治疗向

Sara Moufarrij¹, Higinio Dopeso², David N Brown²

¹Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Gynecologic oncology

|May 9, 2025

概括

子宫癌 (UCS) 经常表达TROP2. 用sacituzumab govitecan针对TROP2在患者衍生模型中显示出有前途的疗效,这表明这种攻击性癌症的潜在新疗法.

科学领域:

妇科瘤学妇科瘤学
癌症治疗方法癌症治疗方法
分子病理学分子病理学

背景情况:

子宫癌 (UCS) 是一种罕见的,激进的子宫内膜癌 (EC) 亚型.
对于UCS治疗,迫切需要新的治疗策略.
在各种固体瘤中,TROP2 是一个新兴的目标.

研究的目的:

为了评估UCS组织中的TROP2表达.
评估TROP2抗体-药物合物 (ADC) 向在患者衍生UCS模型中的有效性.
为了调查sacituzumab govitecan (SG) 作为UCS的潜在治疗方法.

主要方法:

在72个UCS组织中通过免疫组织化学和qRT-PCR分析了TROP2蛋白和mRNA表达.
建立并描述了九种患者衍生UCS有机物 (PDO) 模型.
在UCS PDO和患者衍生异种移植 (PDX) 模型中测试的TROP2 ADC萨基图祖马布戈维特干 (SG) 的有效性.

主要成果:

在≥90%的初级UCS中检测到TROP2表达.
UCS PDOs准确地反映了原发性瘤的分子概况.
所有UCS PDO都对SG有反应,在UCS PDX模型中显著减少瘤体积.

结论:

大多数UCS表现出可检测的TROP2表达.
在临床前UCS模型中,sacituzumab govitecan显示出治疗潜力.
对于UCS患者,需要对TROP2向进行进一步的研究.

关键词:

抗体药物结合物抗体药物结合物这种癌症叫做carcinosarcoma.这是子宫内膜癌的癌症.有机体模型模型

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis

Published on: August 1, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.